Combined mesenchymal and neural stem cell therapy enhances neurological recovery in cerebral infarction

Table 1 Baseline clinical data, mean ± SD

Groups	Observation group	Control group	Statistical value	P value
N	78	78
Gender			0.413	0.521
Male	44	40
Female	34	38
Age (years)	59.0 ± 7.8	57.5 ± 6.5	1.148	0.253
BMI (kg/m2)	22.9 ± 2.7	23.1 ± 2.9	0.444	0.657
Disease duration (hour)	23.9 ± 8.2	24.5 ± 9.3	0.439	0.661
Education level			1.000	0.606
Junior high school and below	28	31
High school and technical secondary school	38	32
College degree or above	12	15
Marital status			3.794	0.150
Unmarried	0	3
Married	71	65
Bereavement	7	10

BMI: Body mass index.

Table 2 Comparison of clinical efficacy between the control and observation groups, n (%)

Group	Control group	Observation group	χ2	P value
N	78	78
Clinical efficacy			6.225	0.013
Recovered	12 (15.4)	6 (7.7)
Markedly effective	18 (23.1)	13 (16.6)
Effective	37 (47.4)	35 (44.9)
Ineffective	11 (14.1)	24 (30.8)
Efficiency	67 (85.95)	54 (69.2)

Table 3 Comparison of neurological function indexes before and after treatment

Group	Control group	Observation group	t	P value
N	78	78
Cerebral perfusion volume (%)
Before	45.1 ± 11.3	47.9 ± 12.4	1.469	0.144
After	52.0 ± 10.4	61.5 ± 16.3	4.341	0.000a
Barthel index
Before	39.2 ± 8.4	41.0 ± 7.1	1.443	0.151
After	58.1 ± 12.3	66.7 ± 10.1	4.758	0.000a
NIHSS scores
Before	10.8 ± 2.9	10.2 ± 3.2	1.151	0.252
After	7.1 ± 0.9	6.5 ± 1.3	3.237	0.001a

^aP < 0.05 vs pre-treatment.

NIHSS: National Institutes of Health Stroke Scale.

Table 4 Comparison of serum vascular endothelial growth factor and basic fibroblast growth factor expression levels between the 2 groups

Group	Control group	Observation group	t	P value
N	78	78
VEGF (pg/mL)
Before	264.6 ± 94.7	247.5 ± 85.6	1.183	0.239
After	530.1 ± 173.3	626.4 ± 197.9	3.233	0.001a
bFGF (pg/mL)
Before	14.1 ± 4.2	14.8 ± 5.3	0.914	0.362
After	23.6 ± 5.3	29.8 ± 6.4	6.590	0.000a

^aP < 0.05 vs pre-treatment.

VEGF: Vascular endothelial growth factor; bFGF: Basic fibroblast growth factor.